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ABSTRACT
Objectives The aim of this study was to determine the
prevalence of infection, genotypes and risk factors for
human papillomavirus (HPV) among men who have sex
with men (MSM) and transgender women living with and
without HIV in Pakistan. Anal infection with HPV is very
common worldwide among MSM, particularly among MSM
living with HIV. The high prevalence of HIV among MSM
and male-to-female transgendered individuals in Pakistan
is a significant health concern since access to screening
and health-seeking is often delayed in this stigmatised key
population.
Design This cross-sectional study was conducted
between March 2016 and November 2017.
Participants, setting and data collection This study
recruited MSM and transgender-women who self-reported
to have had anal sex in the last 6 months, and were
at least 18 years of age, from the sexual health and
antiretroviral therapy centres. Structured questionnaires
were administered, and blood samples were obtained to
confirm HIV status. Anal swabs were collected for HPV-
DNA detection and typing.
Main outcome measures The primary outcome was the
prevalence of ‘HPV-DNA infection’. The prevalence ratios
(PR) were calculated using Cox proportional hazard model
algorithms to analyse the association between exposure
variables and HPV-infection.
Results Complete data were available for 298 MSM
and transgender women (HIV +n=131; HIV−n=167). The
overall HPV-DNA prevalence was 65.1% and was higher in
participants living with HIV as compared with HIV-negative
(87% vs 48%; χ2p≤0.001). Likewise, 28.9% of participants
living with HIV were infected with two or more than two
types of HPV as compared with 18.8% participants without
HIV(χ2 p≤0.001). The most frequent HPV type was HPV6/11
(46.9%), followed by HPV16 (35.1%), HPV18 (23.2%) and
HPV35 (21.1%). HIV status (PR 2.81, 95% CI 2.16 to 3.82)
and never condom use (PR 3.08, 95% CI 1.69 to 5.60))
were independently associated with prevalence of ‘anal-
HPV16 infection’ when adjusting for confounding for age,
other sexual and behavioural factors, for example, smoking
and alcohol consumption.

Strengths and limitations of this study
►► This study is the first description of the epidemiology

of anal human papillomavirus (HPV) infection among
sexual and gender minorities (men who have sex
with men, and transgender women) living with HIV
in Pakistan.
►► Given the strong stigma, homophobia and discrimination against sexual minorities in Pakistan, data
collection included a careful process of gaining trust
among study participants.
►► The results may be of a public health importance
in Pakistan, indicating the need for gender-neutral
HPV vaccination before sexual debut, targeting both
women and men.
►► The cross-
sectional study design precludes any
conclusion on temporal relationships between potential risk factors and the outcome.
►► Any under-
reporting or over-
reporting regarding
sexual behaviours or lifestyle factors leading to information bias cannot be excluded.
Conclusion High prevalence of HPV indicates a
substantial future risk of anal cancer in Pakistani MSM
and transgender women, and particularly in those living
with HIV. Current findings support anal Pap-smear HPV
screening for this particular group and vaccination efforts
for future generations.

INTRODUCTION
Human papillomaviruses (HPV) is the most
common sexually transmitted infection
(STI) worldwide,1 and is rapidly acquired
after sexual debut.2 A meta-analysis of global
data on HPV in men who have sex with men
(MSM) found prevalence rates of anal HPV
to be 93% in MSM living with HIV and 64%
in HIV-
negative MSM, and these rates did
not decrease with increasing age.3 More than
90 genotypes of HPV have been identified
and classified either as low-
risk (LR) types
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(predominantly HPV6 and HPV11) causing genital warts.
High-risk (HR) HPV types (predominantly HPV16 and
HPV18) cause cancer of the cervix,4 its pathogenic role
has also been demonstrated by others with oropharyngeal
cancers.5 6 Persistent infection with HPV16 is the major
cause of anal cancer.7 8 While the burden of HPV-related
disease in all men is lower than in all women, certain at-risk
groups such as MSM and transgender women,9 10 and
particularly those with HIV infection,7 are at HR for HPV
infection, and related anal cancer and its precursor high-
grade squamous intraepithelial lesions.11 The reported
incidence of anal cancer is 1–2/100 000 in the general
population,12 while in MSM it has been reported up to 35
cases per 100 00013 and even up to 131/100 000 in MSM
living with HIV14 15 regardless if they are on antiretroviral
treatment or not.16–18
In Pakistan, the demography of MSM is broadly classified as: MSM who are in relationships but outwardly
closeted; as male sex workers (MSW) who are males and
undertakes receptive anal or oral sexual activity with a
man in return of money or other financial benefits; and as
hijras (transvestites/transgender women) who are biologically male with male genitals but function in society as
if female and take the receptive role in anal sex.19 20 The
‘hijra’ is a South-Asian identity traced back many centuries to India, where they were held in high-esteem and
were political advisors to kings and bodyguards to queens.
Today, however, they often face social exclusion and many
engage in commercial sex work.21
Pakistan is an authoritarian Islamic republic with
conservative social values, particularly on issues of sex.
MSM, and in particular MSW, face high levels of discrimination and contempt from society and are subject to
harassment, sexual violence and detention by the state
authorities. Their health-
seeking behaviours are often
poor due to stigmatisation in healthcare settings and for
the fear of being identified. As a result, they are reluctant to seek healthcare not only in public setups but also
in private facilities. One previous study on sex work and
MSW in Pakistan showed that the majority of MSWs are
poor, have little knowledge about safe sex, and cannot
negotiate the use of condoms and safe sex with their
paying clients, predisposing them to acquiring STIs.20
Pakistan’s national government has lately recognised
MSM as a vulnerable population, and prevention and
control programmes targeting MSMs in its big cities
are being organised (of the estimated 46 264 MSM in
Pakistan, Karachi is home to an estimated 18 361 MSM,
according a survey conducted for mapping key populations in 2015–2016).22 However, programme service
delivery, such as HIV counselling and testing and other
STI screening services, is performed by non-governmental
and community-
based organisations. They are dependent on national and international funders, which has
led to fragmented and incomplete coverage of preventive services for this key population.23 24 Furthermore, the
prevalence of HIV in these groups is reaching alarming
proportions. Results from the fifth round of Integrated
2

Behaviour and Biological second-generation surveillance
for HIV/AIDS in Pakistan 2016–2017 reported over 9%
HIV prevalence in MSM and almost 13% in transgender
women living in Karachi.22
So far there is no research on the burden of HPV
infection and HPV-related anal squamous intraepithelial
lesions in this key population in Pakistan. Currently, HPV
vaccines, in which the bivalent vaccine protects against
HPV16/18 and quadrivalent vaccine protects against
HPV16/18 and the LR types HPV6/11,25 are available in
pharmacies in Pakistan but are not yet made available to
the target population. The Ministry of Health has not yet
included it in their national immunisation programme
for any group in society.
We conducted a cross sectional study in Karachi Pakistan
in 2016–2017 with the objective to determine the prevalence and risk factors for anal HPV infection including
sexual risk behaviours and the association with HPV infection in this dynamic population to inform future policy
and prevention strategies.

METHODS
Setting and participants
Enrolment occurred in two phases for this cross-sectional
study. The initial recruitment (from March 2016 to May
2016) started at the ART clinic with transgender women,
a centre run by the National AIDS Control Programme
of Pakistan in Civil Hospital Karachi (CHK)—the largest
(1900 bed) tertiary care public hospital of Karachi Pakistan (recruited n=33). Low pace, logistic issues and
privacy concerns led to the relocation and setting-
up
of recruitment centre at a sexual health clinic run by a
community-
based organisation, Perwaaz Trust Karachi
Pakistan, where the study population was reached using
snowball technique and peer referrals. During the second
phase between April 2017 and November 2017 a total of
265 study participants with different sexual orientations,
that is, MSM (homosexuals, bisexuals) and transgender
women living with and without HIV were recruited. Participants were eligible for the study who self-reported to
have had anal sex in the last preceding at least 6 months
and were age 18 and above.
Patient and public involvement
No patients or member of the public were involved in the
design, conduct, reporting or dissemination plans of our
study. Data were kept confidential and anonymous and
were used for research purposes only.
Study procedure
Verbal and written informed consent were obtained from
all eligible and willing participants for all study procedures. For participants who could not read or write their
name, a thumb impression was obtained. Participants were
informed that they were free to interrupt the interview or
withdraw from the study at any time without any negative consequences in terms of clinical services provided
Ejaz M, et al. BMJ Open 2021;11:e052176. doi:10.1136/bmjopen-2021-052176
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to them. A 35–40 min long structured questionnaire was
administered at a private space to interview the study
participants in order to collect data concerning sociodemographic information, sexual and reproductive history
and medical history relevant to HIV, any anal disease and
use of ART. A blood sample was obtained for confirmation
of their HIV status (through Architect HIV Ag-Ab Combo
kit by ABBOTT), viral load (real time PCR Artus Qiagen)
and CD4 +T cell count (through FACS Count TM flow
cytometry, Becton Dickinson, Franklin Lakes, New Jersey,
USA). Two anal swabs for HPV testing were collected
by a trained general physician. A water-moistened swab
was inserted 5–6 cm proximal to the anal verge and the
samples were obtained from anorectal transition zone
around the dentate line in the anal canal. The swab was
then agitated vigorously in a tube containing 3 mL of
methanol-
based fixative—a Sample Transport Medium
(UTM-RT viral transport media with flocked polyester
swabs, Copan Diagnostics, Corona, California, USA) and
transported to the lab. In Molecular lab the solution was
stored at −70°C before further processing and was later
used for the extraction and detection of HPV DNA by the
PCR. The DNA from rectal swab was extracted by using
Qiagen DNA mini kit and DNA was eluted in 80 uL of
elution buffer and stored at −80°C for further use. HPV
DNA was detected by using MY09/MY11 primers from
L1 region resulted in amplification of 450 bp of L1 gene.
PCR for Housekeeping gene glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) was done for every extracted
DNA and samples tested negative for GAPDH gene
were excluded from study. Nested multiplex PCR assay
was used26 for detection of HPV subtypes included LR
types 6/11 and HR (group 1) types 16, 18, 31, 33, 35,
52, 56, 58 and 59 as described by Sotlar et al.27 Primers
for first-round PCR for GP-E6/E7 consensus sequence
and second round PCR for HPV subtypes 16, 18, 6/11
31, 33, 35, 52, 56, 58 and 59 were synthesised from Eurofins MWG/Operon Germany. The HPV subtype specific
primers were used in four cocktails and size of the nested
PCR product was used for the identification of each HPV
type by gel electrophoresis.28
Sample size calculation
For the estimation of HPV prevalence, a sample size of
267 participants were needed with an anticipated prevalence of HPV of 50%, 6% precision and 5% level of significance. For the analysis of factors associated with HPV
infection, we aimed for a sample of at least 256 participants to achieve 80% power with a range of exposures
between 9% and 39% and an anticipated prevalence ratio
(PR) of 2.5 or more with 5% level of significance. An
additional sample of 10% was added to cater for inadequate biological samples.
Data management and statistical analysis
The database was analysed using Statistical Package for
Social Sciences (IBM SPSS Statistics for Windows, V.24.0,
IBM).
Ejaz M, et al. BMJ Open 2021;11:e052176. doi:10.1136/bmjopen-2021-052176

The mean value was calculated with standard deviation
(SD) for symmetrically distributed variables and independent sample t-test was used for statistical significance,
while the median with IQRs was used for asymmetrical
quantitative variables. For categorical variables, proportions were employed; for comparison of proportions
between groups, χ2 or Fisher’s exact test (where needed)
were used for p values. The overall HPV DNA prevalence
(as determined by PCR) is reported as the proportion of
HPV positive participants among all included individuals.
Conversely, type-specific HPV positivity is presented as the
proportion of HPV-subtype positive individuals divided
by all HPV positive individuals.7 The CIs for the proportions were estimated using binomial distribution (n,p)
assuming a Gaussian error. Prevalence of ‘any anal HPV
infection’ and ‘any anal HR-HPV infection’ stratified by
HIV status for all reported sexual orientations was also
assessed using Pearson χ2. For multiple comparisons for
each sexual orientation stratified by HIV status for ‘any
anal HPV infection’ and ‘any anal HR-HPV infection’
Bonferroni correction method was used, the p value
threshold was (α/n)=0.05/6=0.0083.
Since the design of the study was cross-sectional and the
outcome of the interest was common (HPV prevalence);
for the association between independent risk factors and
the outcome variables ‘any anal HPV infection’ that is, all
those HPV types that we identified in our study sample
and ‘anal HPV16 infection’, we employed a Cox proportion hazard model algorithm to estimate crude and
adjusted PRs and their 95% CIs in univariate and multivariate models’. Moreover, we employed robust SEs to get
the closest CIs. A significance threshold for the p<0.05
was used for the final model.
RESULTS
Study population characteristics
The final analysis included 298 MSM and transgender
women (235 MSM and 63 transgender women) to assess
the prevalence of HPV DNA in the anal canal. Out of
these 298, 131 (44%) had an HIV-
infection and 167
(56%) were HIV-negative. Among MSM living with HIV,
33 (25%) were transgender women. Almost 90% of the
participants living with HIV were on ART and two thirds
of them had an undetectable HIV viral load.
The overall mean age (±SD) of the 298 recruited
participants was 28.8 (±8.06). The level of education
was low: 28% reported no formal education and 12%
less than primary level. Most respondents were currently
not married. Among study participants almost 78% were
smokers with mean age of smoking initiation 16.5 (±4.9)
and duration of 12 (±8.5) years. Almost 80% were sex
workers, with 12.4 (±8.5) years mean duration of sex
work. The mean age at sexual debut was 16.4 (±4.7) years.
Only 24.2% reported consistent condom use during sex
(table 1).
MSM with any anal HPV infection (n=194) were younger
than MSM without detectable HPV infection (28.9 (±7.3)
3
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Table 1 Sociodemographic and lifestyle characteristics of MSM and transgender women in Karachi, Pakistan by HPV status
Characteristics

Overall (n=298)

HPV positive (n=194)

HPV negative (n=104)

Age categories in years n (%)
 <25

0.254
102 (34.2)

72 (37.1)

30 (28.8)

 25–29

90 (30.2)

59 (30.4)

31 (29.8)

 30–34

41 (13.8)

27 (13.9)

14 (13.5)

 >35

65 (21.8)

36 (18.6)

29 (27.9)

 None

83 (27.9)

56 (29.2)

27 (26.2)

 Primary school

36 (12.1)

29 (15.1)

07 (6.8)

 Middle school

41 (13.8)

24 (12.5)

17 (16.5)

 Matric school

78 (26.2)

49 (25.5)

29 (28.2)

 Intermediate

38 (12.8)

23 (12.0)

15 (14.6)

 Graduate

19 (6.4)

11 (5.7)

08 (7.8)

234 (78.5)

156 (80.4)

78 (75.0)

57 (19.1)

32 (16.5)

25 (24.0)

7 (2.3)

06 (3.1)

01 (1.0)

160 (82.5)

72 (69.2)

Education n (%)

0.334

Marital status n (%)
 Unmarried
 Married
 Separated/divorced

0.256

Smoking status n (%)
 Yes

0.009
232 (77.9)

Average no of cigarettes/day n (%)
 <10

0.035
128 (55.2)

82 (52.9)

46 (63.9)

 10–20

79 (34.1)

52 (33.5)

24 (33.3)

 >20

25 (10.7)

21 (13.5)

2 (2.8)

Alcohol drinking: n (%)
 Yes

0.555
71 (23.8)

44 (23.4)

37 (20.4)

68 (22.8)

39 (20.1)

29 (27.9)

 Homosexual

167 (56.0)

108 (54.6)

 Transgender

63 (21.2)

47 (25.3)

16 (15.4)

237 (79.5)

155 (79.5)

82 (78.8)

Sexual behaviour: n (%)
 Bisexual

 Male sex workers: n (%)

0.127
59 (56.71)

Anal receptive sexual partners during the last 6 months† n (%)
25 (8.4)

16 (8.7)

9 (10.2)

 25–50

36 (12.1)

17 (9.3)

19 (21.6)

 51–100

89 (29.9)

56 (30.6)

33 (37.5)

121 (40.6)

94 (51.4)

27 (30.7)

Condom use during anal receptive sex n (%)
 Consistent use
 Inconsistent use
 Never

<0.001
15 (7.7)

49 (47.1)

175 (58.7)

72 (24.2)

141 (72.7)

41 (39.4)

51 (17.1)

38 (19.6)

14 (13.5)

264 (88.6)

173 (89.2)

81 (77.9)

34 (11.4)

21 (10.8)

23 (22.1)

167 (56.0)

133 (68.6)

34 (32.7)

20 (10.3)

13 (12.5)

174 (89.7)

91 (87.5)

Preferred anal sex role n (%)
 Mainly receptive
 Mainly insertive
Other STI (gonorrhoea, Trichomonas) n (%)

0.009

 CBO

<0.001
0.566

Recruitment settings n (%)
 ART

0.83
0.004

 <25

 >100

P value*

33 (11)
265(89)

Continued
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Table 1 Continued
Characteristics

Overall (n=298)

HPV positive (n=194)

HPV negative (n=104)

P value*

* χ2 test was used for p values.
†Missing values=9.1%.
ART, Anti retroviral therapy; CBO, Community based organisation; HPV, human papillomavirus; MSM, men who have sex with men; STI, sexually
transmitted infection.

vs 30.2 (±9.1) years; independent sample t-test p=0.027).
Smoking was more prevalent among HPV-positive MSM
(82.5% vs 69.2%) than among those uninfected, with a
significant difference in mean age (±SD) of 15.6 (±4.5)
years at smoking initiation. The mean age (±SD) at sexual
debut among study participants with an HPV infection
was 15.7 (±4.3) vs 17.6 (±5.2) (independent sample
t-test-p=0.001). HPV-infected had more sexual partners,
more inconsistent condom users and more often practised receptive anal sex (table 1).
MSM living with HIV were, however, older than MSM
who were HIV negative (mean (±SD): 30.9 (±0.70) vs
27.2 (±0.59) independent sample t-test p≤0.001), more
frequently smokers (χ2p=0.01), younger at initiation of
smoking (independent sample t-test p≤0.001) and had
smoked for a longer duration of time ((χ2p≤0.001).
They also reported younger age at sexual debut (independent sample t-test p≤0.001), had more sexual clients
(χ2p≤0.001), were mainly the receptive anal partner
(χ2p≤0.001) and used condoms less consistently than
their HIV negative counterparts (χ2p≤0.001).
Sexual orientation of the study sample
Among participants living with HIV, 45.1% reported their
sexual orientation as homosexual, 29.8% as bisexuals and
25.1% as transgender women. The sexual orientations
reported by HIV uninfected participants were, 64.7%
as homosexuals, 17.3% as bisexuals and 18.0% as transgender women.
HPV DNA prevalence and genotype distribution
Overall, 65.1% (n=194/298) of the total study population was positive for HPV DNA (95% CI 59.5% to 70.3%).
MSM living with HIV had a significantly higher prevalence of HPV (87% (95% CI 80.0% to 91.0%)) compared
with those who did not have HIV (48% (95% CI 40.0%
to 55.0%)) as well as any oncogenic anal HPV infection
(83.2% (95% CI 75.8% to 88.6%) verses (35.3% (95% CI
28.4% to 42.8%). Likewise, 28.9% of participants living
with HIV were infected with two or more than two types
of HPV as compared with 18.8% participants without
HIV (χ2p≤0.001). The most common HPV types were
HPV6/11 (46.9%), HPV16 (35.1%), HPV18 (23.2%),
HPV35 (21.1%) and HPV58 (8.2%). Moreover, the distribution of HPV6/11 was more among HIV uninfected
participants (61.3%) as compared with HIV infected
participants (36.8%) ((χ2p=0.001). However, HPV16 was
more common among HIV infected participants (44.7%
verses 21.2%) and the difference was statistically significant (χ2p=0.001) (table 2).
Ejaz M, et al. BMJ Open 2021;11:e052176. doi:10.1136/bmjopen-2021-052176

HPV DNA prevalence by HIV status and sexual orientation
For participants living with HIV, the prevalence of ‘any
anal HPV infection’ were 88.1% for homosexual men,
76.9% for bisexual men and 96.9% for transgender
women and the prevalence for ‘Any anal HR-
HPV
infection’ was 74.5%, 51.3% and 81.8%, respectively
(χ2p=0.001) (figure 1).
For HIV uninfected participants, the prevalence of
‘any anal HPV infection’ was 50.9% for homosexual men,
31.0% for bisexual men and 53.4% for transgender women
and the prevalence for ‘any anal HR- HPV infection’ was
37.1%, 20.7% and 43.3%, respectively. (χ2p=0.001).
Post hoc analysis with the Bonferroni correction
method determined that the homosexuals were significantly different with being infected with ‘any anal HPV
infection’ and ‘any anal HR-HPV infection’ (χ2p=0.0014
and 0.0019) when compared with bisexuals and transgender women living with and without HIV.
Independent variables associated with anal HPV infection
Being HIV positive (PR 2.81 (95% CI 2.16 to 3.82)) and
inconsistent/never condom use (PR 2.61 (95% CI 1.50
to 4.50)/(PR 3.08 (95% CI 1.69 to 5.60) were independent risk factors associated with increased prevalence of
HPV16 infection, adjusted for all other demographic,
sexual and behavioural risk factors (table 3).

DISCUSSION
To the best of our knowledge, this is the first report on
anal HPV infection among MSM living with and without
HIV in Pakistan. The high prevalence of anal HPV among
MSM living with HIV (87%) in Pakistan is similar to Thailand (85.0%)29 and China (81%–82%),30 31 slightly lower
than in neighbouring India (95%)32 and Canada (98%),33
but significantly higher than what has been reported
from the Netherlands (65%).34 In HIV-negative MSM,
however, studies previously carried out in the USA and
Latin America showed similar prevalence levels of HPV
prevalence ranging from 42% to 66%, which is comparable to our 48%.35–37 In Pakistan, there is heterogeneity
among MSMs, and it is predominantly MSWs who register
with the community-based organisations with a hope to
get free medical services of any kind in a secluded setting.
It is MSW who accounted for 80% of our study population, partly explaining the differences in the prevalence
of anal HPV infection between our study and others. In
a study from India, which has similar social and cultural
values, Hernandez et al32 noticed HPV prevalence of 98%
5
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Table 2 Distribution of HPV types among MSM and transgender women in Karachi, Pakistan stratified by HIV status
ALL

HPV among HIV positive

HPV among HIV negative

HPV types

n (%)

n (%)

n (%)

P value*

Any type

194 (65.1)

114 (58.8) 87.0

80 (41.2) 48.0

<0.0001

HR types
 HPV 16

68 (35.1)

51 (44.7)

17 (21.2)

0.001

 HPV 18

45 (23.2)

30 (26.3)

15 (18.8)

0.219

 HPV 31

14 (7.2)

8 (7.5)

6 (7.0)

 HPV 33

13 (6.7)

13 (11.4)

0 (0.0)

0.898
NC

 HPV 35

41 (21.1)

25 (21.9)

16 (20.0)

0.746

 HPV 45

14 (7.2)

6 (5.3)

9 (11.3)

0.124

 HPV 52

13 (6.7)

4 (3.5)

9 (11.3)

0.043†

 HPV 58

16 (8.2)

13 (11.4)

3 (3.8)

0.066†

 HPV 59

21 (10.8)

10 (8.8)

11 (13.8)

0.272

 HPV 56

15 (7.7)

8 (7.0)

7 (8.8)

0.657

91 (46.9)

42 (36.8)

49 (61.3)

0.001

 Bivalent vaccine type
 HPV 16 & /18

107 (55.2)

75 (65.8)

32 (40.0)

0.000

 4-valent vaccine type
 HPV 6/11/16/18

163 (84.0)

94 (82.4)

69 (86.2)

0.478

 9-valent vaccine type‡
 HPV 6/11/16/18/31
 /33/45/52/58

181 (93.3)§

105 (92.1)

76 (95.0)

0.427

 Low risk types
 HPV 6/11
Vaccine specific types

* χ2 test was used for p values.
†Fisher’s exact test.
‡Includes 9-valent all types which come as alone, in combination with other 9-valent specific types or in combination with non-9-valent
HR types such as HPV type 35, when we excluded HPV 35 (n=33).
§93.3% changed to 76.3%.
HPV, human papillomavirus; HR, high-risk; MSM, men who have sex with men; NC, not calculated.

Figure 1 Prevalence of any HPV and HR-HPV by HIV status
and sexual orientation. HPV, human papillomavirus; HR, high-
risk.
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in MSM living with HIV and commented on the fluid
nature of sexual identity without mentioning the exact
prevalence of MSW among them. Moreover, given the
fact that our study has a cross-sectional design, incubation
time for infection and variation in viral clearance could
be other possible explanations for the differences in the
prevalence.29 38
For the distribution of anal HPV types, our study
results are similar to the studies done elsewhere.39 HPV16
(35.1%) was the most common anal oncogenic HPV
type detected both in MSM living with and without HIV
(44.7% vs 21.2%, p<0.001). This is in close approximation
of the summary prevalence for HPV16 calculated from
a recent meta-analyses7 40 and by others.29 33 41 42 HPV16
has the ability to persist in the anal canal more than any
other types and not only tends to cause anal intraepethilial neoplasia (AIN)29 but also associated with disease
severity.7
The prevalence of HR-HPV type 35 (21.1%) in our
study was similar to the levels reported by India (20%),32
but higher than HPV type 35 levels reported from other
parts of the world.31–33 Given the fact that HPV35 is not
Ejaz M, et al. BMJ Open 2021;11:e052176. doi:10.1136/bmjopen-2021-052176
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Table 3 Factors associated with any type of detectable HPV infection and HPV type 16, among MSM and transgender
women in Karachi Pakistan (N=298)

Risk factors

HPV positive
N (%)

Any anal HPV
infection
Crude PR (95% CI)

Any anal HPV
Anal HPV
infection
16—infection
Adjusted PR (95% CI) Crude PR (95% CI)

Anal HPV
16—infection
Adjusted PR (95% CI)

HIV status
 No (ref)
 Yes

80 (48.0)
114 (87.0)

1.0
1.81 (1.36 to 2.4)

1.44 (1.05 to 1.97)

1.0
3.33 (2.55 to 3.51)

1.0
2.81 (2.16 to 3.82)

Other STI*
 No (ref)
 Yes

61 (31.4)
133 (68.6.0)

1.0
1.32 (1.08 to 2.13)

1.0
1.29 (1.02 to 1.91)

1.0
1.97 (1.28 to 3.04)

1.0
1.52 (0.99 to 2.37)

Preferred anal sex role
 Insertive (ref)
 Receptive

21 (10.8)
173 (89.2)

1.0
1.95 (1.09 to 3.50)

1.0
1.56 (0.87 to 2.83)

1.0
2.49 (1.02 to 6.14)

Condom use
 Consistent (ref)
 Inconsistent
 Never

15 (7.7)
141 (72.7)
38 (19.6)

1.0

1.0

1.0

1.0

3.30 (1.94 to 5.6)

2.01 (1.07 to 5.20)

2.96 (1.48 to 5.92)

2.61 (1.50 to 4.50)

2.42 (1.04 to 5.21)

1.58 (1.03 to 4.44)

3.11 (1.71 to 5.66)

3.08 (1.69 to 5.60)

Smoking
 No

34 (17.5)

 Yes

160 (82.5)

1.0
1.34 (0.93 to 1.93)

1.0
1.17 (0.71 to 1.90)

*Trichomonas, gonorrhoea.
†All significant variables were adjusted for age, sociodemographic and all other sexual behaviours.
HPV, human papillomavirus; MSM, men who have sex with men; PR, prevalence ratio; STI, sexually transmitted infection.

included in the FDA-approved 9-valent vaccine, its relatively high prevalence can have implications on anal
cancer prevention in our region.
Similar to previous research,43 our results also revealed
that almost 4 out of 5 MSM carried at least one of the HR
genotypes in their anal canal (80% MSM living with HIV
vs 73% of MSM without HIV infection). This is of concern
in HIV-negative MSM in particular, since infection with
HR-HPV types is reported to increase the likelihood of
acquiring HIV.16 Thus, our results further emphasise the
need to screen Pakistani MSM more frequently for both
HPV and HIV given their HR of development of malignant disease.
Our study detected a high prevalence of multiple HPV
types—that is, at least 2 types (either LR and HR or HR
& HR)—of 47% in HPV positive MSM as a group, which
is similar to other, studies.44 This indeed is a matter of
concern as anal infection with multiple HR-HPV types
increases the likelihood of an individual to be infected
with HPV16 and, infection with HPV16 has been associated with AIN and progression to higher grade AIN over
time.3 Moreover, its prevalence was significantly higher
in MSM living with HIV. Higher HPV reinfection rates
and lower clearance rates in individuals living with HIV
may also play a crucial role in the development and the
progression of anal neoplastic disease.29 45
The results of our study suggest that the most frequently
distributed HPV types among Pakistani MSM could be
covered by the currently available nonavalent (93.3%)
Ejaz M, et al. BMJ Open 2021;11:e052176. doi:10.1136/bmjopen-2021-052176

and quadrivalent (84%) vaccines, which means that most
of HPV-related diseases including cancers and anogenital
warts may potentially be preventable if offered to MSM
at initiation of sexual debut. However, the 20% carrying
HPV35 would not be covered by the currently available
vaccines.
More than 50% of HPV-
positive MSM were young,
below 25 years of age, most were single and sexually very
active, and most make a living and support their families
through sex work.46 As many as 80% of HPV-positive MSM
had initiated sex work in their teens, which is in line with
other studies.47 The high number of parallel sexual partners may contribute to further spread of HPV and other
STIs among MSM.
Among other sexual behaviours, inconsistent or never
use of condom was the only variable that was significantly
associated with any HPV, specifically HPV16 infection.
For many in our study population, negotiating safe sex
is not an option as, on an average, a MSW will service
3–5 clients per night with a one-time service charge as
low as PKR100–PKR150 (US$0.7–US$1.03),19 48 though
higher rates may be charged for unprotected sex. Thus,
financial barriers may impede consistency in condom
use. In addition, receptive anal sex was significantly more
common among HPV-infected MSM, considering the fact
that this is the strong transmission route and poses HR
for HIV acquisition.49 Since the prevalence of anal HPV
was more than twice as common in MSM and transgender
women living with HIV, this finding indeed turned out
7
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to be consistent with our multiple regression model that
identified HIV infection as an independent risk factor for
any anal HPV or HPV16 infection confirming MSM and
transgender women living with HIV as a priority for the
prevention of anal cancer.40
Limitations of the study
Our study had some limitations. First, the design of the
study was cross-sectional, yet many HPV infections are
non-persistent in nature.50 Moreover, the cross-sectional
design precludes us to determine a temporal relationship,
however, the risk factors identified in our study appear
robust and have also been found in studies from other
countries. Second, our study results may have limited
generalisability because participants were recruited from
only one city of Pakistan (Karachi) and were recruited
using peer referrals and snowball sampling techniques.
Nevertheless, Karachi is the largest metropolitan city
of Pakistan, representing all ethnicities of the country.
Moreover, in a country like Pakistan, which is by and
large a heteronormative society and where homophobia
prevails against this sexual minority due to cultural and
religious inhibitions, using above-
mentioned sampling
technique was the most feasible option for the recruitment process. Third, we cannot exclude the possibility of
under-reporting or over-reporting of sexual behaviours
and lifestyle factors that could not only influence the
strength of association with the outcome but might also
lead to information bias since they were self-reported.
Recommendations
HIV care and treatment programmes in Pakistan represent a potential window of opportunity for providing
preventive clinical interventions to avert an anal cancer
epidemic nested within the HIV epidemic. Providing
cost-effective, life-saving anal cancer prevention services
(ie, screen and treat approach and vaccination) linked to
HIV care could not only avert preventable HPV-related
malignancies but could also lead to a more efficient utilisation of resources and improve healthcare access for
those most at risk. Moreover, our study findings emphasise the need for government support of interventions
that can improve access to and quality of services to MSM
including MSW. Prevalent cultural and social stigma must
also be addressed since this is essential for protecting the
dignity and autonomy of this population.
Conclusions
We believe that our study findings are of importance for
clinical practice and public health policy. The relatively
high prevalence of HR HPV indicates a future risk of anal
cancer among MSM in general and among MSM living
with HIV in particular. Given that HPV35 currently is not
included in the 9-valent HPV vaccine, we strongly feel
that this is one of our most important contributions and
that there is a need for regular anal pap screening among
MSM and transgender women to enable early detection
and treatment to prevent anal cancer.
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